Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling

Immunovant Inc. (NASDAQ:IMVT) is one of the promising stocks to buy under $50. On January 8, Truist analyst Danielle Brill raised the firm’s price target on Immunovant to $22 from $16, while maintaining a Hold rating on the shares. While the firm updated its financial model, Truist informed investors that its core fundamental outlook remains unchanged from 2025.

On January 6, Wolfe Research upgraded Immunovant from Peer Perform to Outperform with a $50 price target and noted a shift in market sentiment regarding Graves’ disease. While the firm previously expected a valuation re-rating to take years, Argenx’s entry into the Graves’ market established a higher valuation floor by increasing investor appreciation for the space. Wolfe Research highlighted the shrinking short float as a sign of growing market confidence.

Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling

Guggenheim analyst Yatin Suneja maintained a Buy rating on Immunovant Inc. (NASDAQ:IMVT) earlier on December 18 but lowered the price target to $41 from $44. This adjustment followed the company’s then-recent $550 million equity offering, which the firm noted will lead to a higher share count and some stock dilution. However, Guggenheim pointed out that this is balanced by a strengthened balance sheet and an extended cash runway, supporting the company’s continued development.

Immunovant Inc. (NASDAQ:IMVT) is a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases.

While we acknowledge the potential of IMVT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMVT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.